Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC).
Bradley A. McGregor(Harvard University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Alex Chehrazi‐Raffle(City of Hope), Toni K. Choueiri(Harvard University), Pedro C. Barata(University Hospitals Seidman Cancer Center), Claudia Lebedinsky(European Institute of Oncology), Benjamin Garmezy(Sarah Cannon), Rana R. McKay(University of California San Diego), Edgar Braendle(AVEO Oncology (United States)), Roberto Iacovelli(Agostino Gemelli University Polyclinic), Laurence Albigès(Université Paris-Saclay), Monette Cotreau(HealthPartners), Bo Jin, Philippe Barthélémy(Institut de Cancérologie Strasbourg), Hans J. Hammers(Southwestern Medical Center), Daniel Yick Chin Heng(University of Calgary), Sheik Emambux(Centre Hospitalier Universitaire de Poitiers), Katy Beckermann(Vanderbilt University Medical Center), Javier Molina‐Cerrillo(Hospital Universitario Ramón y Cajal)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k